Wednesday, July 8, 2026
🇺🇸 FDA

pharma · COVID-19 · Poliomyelitis

Sinovac Research and

Sinovac Research and Development Co.,

Sinovac Research and clinical programs — 115 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Dhaka, CN HQ
2022 Founded
9 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Dhaka, CN
Founded
2022
Employees
9
Programs
115
Drugs
54
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Sinovac Research and projects

115 ClinicalTrials.gov programs sponsored by Sinovac Research and.

Sinovac Research and has 115 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

115 programs

Clinical programs

Page 1 of 3

  1. 36-71 months old children-experimental EV71 vaccine.

    Sinovac Research and Development Co.,

    Hand, Foot and Mouth Disease

    phase 3 mab completed

    1 trial

  2. 400U /0.5ml EV71 vaccine

    Sinovac Research and Development Co.,

    Hand, Foot and Mouth Disease

    phase 3 mab completed

    1 trial

  3. Adsorbed COVID-19 (inactivated) Vaccine

    Sinovac Research and Development Co.,

    COVID-19

    phase 3 mab completed

    1 trial

  4. COVID-19 Vaccine,Inactivated

    Sinovac Research and Development Co.,

    COVID-19

    phase 3 mab completed

    1 trial

  5. Experimental vaccine

    Sinovac Research and Development Co.,

    Poliomyelitis

    phase 3 mab completed

    1 trial

  6. Inactivated COVID-19 Vaccine

    Sinovac Research and Development Co.,

    COVID-19

    phase 3 mab completed

    4 trials

  7. Investigational live attenuated mumps vaccine

    Sinovac Research and Development Co.,

    Mumps

    phase 3 mab completed

    2 trials

  8. Investigational sIPV

    Sinovac Research and Development Co.,

    Poliomyelitis

    phase 3 mab completed

    1 trial

  9. Investigational tetanus vaccine, adsorbed

    Sinovac Research and Development Co.,

    Tetanus

    phase 3 mab completed

    1 trial

  10. Medium-dosage COVID-19 Vaccine,Inactivated

    Sinovac Research and Development Co.,

    COVID-19

    phase 3 mab terminated

    1 trial

  11. PRO-EV71CA16-3001

    Sinovac Research and Development Co.,

    Hand, Foot, and Mouth Disease（HFMD)

    phase 3 mab active

    1 trial

  12. PRO-PVRV-sf-3003

    Sinovac Research and Development Co.,

    Rabies

    phase 3 mab active

    2 trials

  13. PRO-QINF-3004

    Sinovac Research and Development Co.,

    Seasonal Influenza

    phase 3 mab completed

    1 trial

  14. PRO-VZV-4002

    Sinovac Research and Development Co.,

    Varicella

    phase 3 mab active

    1 trial

  15. PRO-nCOV-3001

    Sinovac Research and Development Co.,

    Covid19

    phase 3 mab completed

    1 trial

  16. PRO-onCOV-3001

    Sinovac Research and Development Co.,

    COVID-19

    phase 3 mab completed

    1 trial

  17. PRO-sIPV-3002

    Sinovac Research and Development Co.,

    Poliomyelitis

    phase 3 mab completed

    1 trial

  18. PRO-tnCOV-3003

    Sinovac Research and Development Co.,

    COVID-19

    phase 3 mab active

    1 trial

  19. PROVARIX

    Sinovac Research and Development Co.,

    Varicella (Chickenpox)

    phase 3 mab active

    1 trial

  20. Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV

    Sinovac Research and Development Co.,

    Influenza

    phase 3 mab active

    1 trial

  21. Quadrivalent influenza vaccine

    Sinovac Research and Development Co.,

    Seasonal Influenza

    phase 3 mab completed

    2 trials

  22. Quadrivalent influenza vaccine(0.25ml)

    Sinovac Research and Development Co.,

    Seasonal Influenza

    phase 3 mab completed

    2 trials

  23. Rabies vaccine

    Sinovac Research and Development Co.,

    Rabies (Healthy Volunteers)

    phase 3 mab active

    1 trial

  24. SARS-CoV-2 inactivated vaccine

    Sinovac Research and Development Co.,

    Covid19

    phase 3 mab completed

    1 trial

  25. SARS-CoV-2 vaccine (inactivated)

    Sinovac Research and Development Co.,

    SARS-CoV2 Infection

    phase 3 mab completed

    1 trial

  26. Sabin Strain Inactivated Poliovirus Vaccine

    Sinovac Research and Development Co.,

    Poliomyelitis

    phase 3 mab completed

    1 trial

  27. Sinovac PCV13

    Sinovac Research and Development Co.,

    Pneumococcal Infectious Diseases

    phase 3 mab active

    1 trial

  28. Sinovac PCV13

    Sinovac Research and Development Co.,

    Pneumococcal Infectious Disease

    phase 3 mab active

    2 trials

  29. Sinovac rabies vaccine

    Sinovac Research and Development Co.,

    Rabies (Healthy Volunteers)

    phase 3 mab active

    2 trials

  30. Tetravalent influenza vaccine developed by Sinovac Biotech Co.

    Sinovac Research and Development Co.,

    Influenza

    phase 3 small molecule active

    1 trial

  31. Vaccine manufactured at commercialized scale

    Sinovac Research and Development Co.,

    Varicella

    phase 3 mab completed

    1 trial

  32. Varicella Vaccine

    Sinovac Research and Development Co.,

    Varicella

    phase 3 mab completed

    1 trial

  33. Varicella Vaccine

    Sinovac Research and Development Co.,

    Varicella (Chickenpox)

    phase 3 mab active

    1 trial

  34. experimental vaccine

    Sinovac Research and Development Co.,

    Epidemic Meningitis

    phase 3 mab active

    4 trials

  35. sIPV-bOPV-bOPV vaccination schedule

    Sinovac Research and Development Co.,

    Poliomyelitis

    phase 3 mab completed

    1 trial

  36. sIPV-sIPV-bOPV vaccination schedule

    Sinovac Research and Development Co.,

    Poliomyelitis

    phase 3 mab completed

    1 trial

  37. three consecutive lots of EV71 vaccine

    Sinovac Research and Development Co.,

    Hand, Foot and Mouth Disease

    phase 3 mab completed

    1 trial

  38. 100U EV71 vaccine with adjuvant

    Sinovac Research and Development Co.,

    Infection, Viral, Enterovirus

    phase 2 mab completed

    1 trial

  39. 400 U EV71 vaccine with adjuvant

    Sinovac Research and Development Co.,

    Infection, Viral, Enterovirus

    phase 2 mab terminated

    1 trial

  40. CoronaVac®

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 mab completed

    1 trial

  41. Low-dose experimental vaccine

    Sinovac Research and Development Co.,

    Herpes Zoster

    phase 2 mab active

    1 trial

  42. Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell)

    Sinovac Research and Development Co.,

    Hand, Foot, and Mouth Disease (HFMD)

    phase 2 mab completed

    1 trial

  43. Oral hexavalent reassortant rotavirus attenuated live vaccine

    Sinovac Research and Development Co.,

    Rotavirus Gastroenteritis

    phase 2 mab active

    2 trials

  44. PRO-EV71/CA16-1001

    Sinovac Research and Development Co.,

    Hand, Foot and Mouth Disease

    phase 2 mab active

    1 trial

  45. PRO-nCOV-1002

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 mab completed

    2 trials

  46. PRO-nCOV-1003

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 mab completed

    1 trial

  47. PRO-nCOV-2002

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 mab on hold

    1 trial

  48. PRO-nCOV-2004

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 mab terminated

    1 trial

Frequently asked questions

How many clinical projects does Sinovac Research and have?

115 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.